Efficacy and Safety Factors Related to Plasma Concentration-Optimized Polymyxin B Therapy in Treating Carbapenem-Resistant Gram-Negative Bacterial Infections in China

References

• Patel G, Bonomo RA. “Stormy waters ahead”: global emergence of carbapenemases. Front Microbiol. 2013;4:48. doi:10.3389/fmicb.2013.00048
   PubMed Web of Science ®Google Scholar
• Paul M, Daikos GL, Durante-Mangoni E, et al. Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial. Lancet Infect Dis. 2018;18(4):391–400. doi:10.1016/s1473-3099(18)30099-9
   PubMed Web of Science ®Google Scholar
• Teng CB, Koh PT, Lye DC, et al. Continuous versus intermittent infusion of polymyxin B in the treatment of infections caused by multidrug-resistant Gram-negative bacteria. Int J Antimicrob Agents. 2008;31(1):80–82. doi:10.1016/j.ijantimicag.2007.08.004
   PubMed Web of Science ®Google Scholar
• Ouderkirk JP, Nord JA, Turett GS, et al. Polymyxin B nephrotoxicity and efficacy against nosocomial infections caused by multiresistant gram-negative bacteria. Antimicrob Agents Chemother. 2003;47(8):2659–2662. doi:10.1128/aac.47.8.2659-2662.2003
   PubMed Web of Science ®Google Scholar
• Parchuri S, Mohan S, Cunha BA. Extended spectrum beta-lactamase-producing Klebsiella pneumoniae chronic ambulatory peritoneal dialysis peritonitis treated successfully with polymyxin B. Heart Lung. 2005;34(5):360–363. doi:10.1016/j.hrtlng.2004.11.00
   PubMed Web of Science ®Google Scholar
• Sarria JC, Angulo-Pernett F, Kimbrough RC, et al. Use of intravenous polymyxin B during continuous venovenous hemodialysis. Eur J Clin Microbiol Infect Dis. 2004;23(4):340–341. doi:10.1007/s10096-004-1106-8
   PubMed Web of Science ®Google Scholar
• Pereira GH, Muller PR, Levin AS. Salvage treatment of pneumonia and initial treatment of tracheobronchitis caused by multidrug-resistant Gram-negative bacilli with inhaled polymyxin B. Diag Microbiol Infect Dis. 2007;58(2):235–240. doi:10.1016/j.diagmicrobio.2007.01.008
   PubMed Web of Science ®Google Scholar
• Falagas ME, Bliziotis IA, Tam VH. Intraventricular or intrathecal use of polymyxins in patients with Gram-negative meningitis: a systematic review of the available evidence. Int J Antimicrob Agents. 2007;29(1):9–25. doi:10.1016/j.ijantimicag.2006.08.024
   PubMed Web of Science ®Google Scholar
• Tsuji BT, Pogue JM, Zavascki AP, et al. International Consensus Guidelines for the Optimal Use of the Polymyxins: endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). Pharmacotherapy. 2019;39(1):10–39. doi:10.1002/phar.2209
   PubMed Web of Science ®Google Scholar
• Elias LS, Konzen D, Krebs JM, et al. The impact of polymyxin B dosage on in-hospital mortality of patients treated with this antibiotic. J Antimicrob Chemother. 2010;65(10):2231–2237. doi:10.1093/jac/dkq285
   PubMed Web of Science ®Google Scholar
• Yang J, Liu S, Lu J, et al. An area under the concentration-time curve threshold as a predictor of efficacy and nephrotoxicity for individualizing polymyxin B dosing in patients with carbapenem-resistant gram-negative bacteria. Critical Care. 2022;26(1):320. doi:10.1186/s13054-022-04195-7
   PubMed Web of Science ®Google Scholar
• Thomas R, Velaphi S, Ellis S, et al. The use of polymyxins to treat carbapenem resistant infections in neonates and children. Exp Opin Pharmacother. 2019;20(4):415–422. doi:10.1080/14656566.2018.1559817
   PubMed Web of Science ®Google Scholar
• Wang P, Zhang Q, Qin Z, et al. A simple and robust liquid chromatography with tandem mass spectrometry analytical method for therapeutic drug monitoring of plasma and cerebrospinal fluid Polymyxin B1 and B2. Ther Drug Monit. 2020;42(5):716–723. doi:10.1097/ftd.0000000000000754
   PubMed Web of Science ®Google Scholar
• Pai MP, Neely M, Rodvold KA, et al. Innovative approaches to optimizing the delivery of vancomycin in individual patients. Adv Drug Delivery Rev. 2014;77:50–57. doi:10.1016/j.addr.2014.05.016
   PubMed Web of Science ®Google Scholar
• Pierce CB, Muñoz A, Ng DK, et al. Age- and sex-dependent clinical equations to estimate glomerular filtration rates in children and young adults with chronic kidney disease. Kidney Int. 2021;99(4):948–956. doi:10.1016/j.kint.2020.10.047
   PubMed Web of Science ®Google Scholar
• Ismail B, Shafei MN, Harun A, et al. Predictors of polymyxin B treatment failure in Gram-negative healthcare-associated infections among critically ill patients. J Microbiol Immunol Infect. 2018;51(6):763–769. doi:10.1016/j.jmii.2017.03.007
   PubMedGoogle Scholar
• Vicari G, Bauer SR, Neuner EA, et al. Association between colistin dose and microbiologic outcomes in patients with multidrug-resistant gram-negative bacteremia. Clinl Infect Dis. 2013;56(3):398–404. doi:10.1093/cid/cis909
   PubMed Web of Science ®Google Scholar
• Xia GL, Jiang RL. Efficacy and safety of polymyxin B in carbapenem-resistant gram-negative organisms infections. BMC Infect Dis. 2021;21(1):1034. doi:10.1186/s12879-021-06719-y
   PubMed Web of Science ®Google Scholar
• Scudeller L, Righi E, Chiamenti M, et al. Systematic review and meta-analysis of in vitro efficacy of antibiotic combination therapy against carbapenem-resistant Gram-negative bacilli. Int J Antimicrob Agents. 2021;57(5):106344. doi:10.1016/j.ijantimicag.2021.106344
   PubMed Web of Science ®Google Scholar
• Samal S, Samir SB, Patra SK, et al. Polymyxin Monotherapy vs. Combination therapy for the treatment of multidrug-resistant infections: a systematic review and meta-analysis. Indian J Crit Care Med. 2021;25(2):199–206. doi:10.5005/jp-journals-10071-23720
   PubMed Web of Science ®Google Scholar
• Ardebili A, Izanloo A, Rastegar M. Polymyxin combination therapy for multidrug-resistant, extensively-drug resistant, and difficult-to-treat drug-resistant gram-negative infections: is it superior to polymyxin monotherapy? Exp Rev Anti-Infective Ther. 2023;21(4):387–429. doi:10.1080/14787210.2023.2184346
   PubMed Web of Science ®Google Scholar
• Tang T, Li Y, Xu P, et al. Optimization of polymyxin B regimens for the treatment of carbapenem-resistant organism nosocomial pneumonia: a real-world prospective study. Critical Care. 2023;27(1):164. doi:10.1186/s13054-023-04448-z
   PubMed Web of Science ®Google Scholar
• Qiao L, Zuo W, Yang Y, et al. Clinical outcomes and safety of intravenous polymyxin B-based treatment in critically ill patients with carbapenem-resistant Acinetobacter baumannii nosocomial pneumonia. Int J Antimicrob Agents. 2023;62(2):106880. doi:10.1016/j.ijantimicag.2023.106880
   PubMed Web of Science ®Google Scholar
• Lin H, Liu X, Sun P. Effects of aerosol inhalation combined with intravenous drip of polymyxin b on bacterial clearance, symptoms improvement, and serum infection indexes in patients with pneumonia induced by multidrug-resistant gram-negative bacteria. Emer Med Int. 2022;2022:5244538. doi:10.1155/2022/5244538
   PubMed Web of Science ®Google Scholar
• Landersdorfer CB, Wang J, Wirth V, et al. Pharmacokinetics/pharmacodynamics of systemically administered polymyxin B against Klebsiella pneumoniae in mouse thigh and lung infection models. J Antimicrob Chemother. 2018;73(2):462–468. doi:10.1093/jac/dkx409
   PubMed Web of Science ®Google Scholar
• Cheah SE, Wang J, Nguyen VT, et al. New pharmacokinetic/pharmacodynamic studies of systemically administered colistin against Pseudomonas aeruginosa and Acinetobacter baumannii in mouse thigh and lung infection models: smaller response in lung infection. J Antimicrob Chemother. 2015;70(12):3291–3297. doi:10.1093/jac/dkv267
   PubMed Web of Science ®Google Scholar
• Erb CT, Patel B, Orr JE, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia. Ann Am Thoracic Soc. 2016;13(12):2258–2260. doi:10.1513/AnnalsATS.201608-641CME
   PubMed Web of Science ®Google Scholar
• Wu M, Zou ZY, Chen YH, et al. Severe COVID-19-associated sepsis is different from classical sepsis induced by pulmonary infection with carbapenem-resistant Klebsiella pneumonia (CrKP). Chin J Traumatol. 2022;25(1):17–24. doi:10.1016/j.cjtee.2021.11.001
   PubMed Web of Science ®Google Scholar
• de Souza GHA, de Oliveira AR, Dos Santos Barbosa M, et al. Multidrug-resistant gram-negative bacteria in patients with COVID-19: an epidemiological and clinical study. J Infect Pub Health. 2023;16(8):1184–1192. doi:10.1016/j.jiph.2023.05.017
   PubMed Web of Science ®Google Scholar
• Hanafin PO, Kwa A, Zavascki AP, et al. A population pharmacokinetic model of polymyxin B based on prospective clinical data to inform dosing in hospitalized patients. Clin Microbiol Infect. 2023;29(9):1174–1181. doi:10.1016/j.cmi.2023.05.018
   PubMed Web of Science ®Google Scholar
• Wang P, Xing H, Zhang F, et al. Population pharmacokinetics of polymyxin B in critically ill patients receiving continuous venovenous haemofiltration. Int J Antimicrob Agents. 2022;60(1):106599. doi:10.1016/j.ijantimicag.2022.106599
   PubMed Web of Science ®Google Scholar
• Rigatto MH, Falci DR, Lopes NT, et al. Clinical features and mortality of patients on renal replacement therapy receiving polymyxin B. Int J Antimicrob Agents. 2016;47(2):146–150. doi:10.1016/j.ijantimicag.2015.11.007
   PubMed Web of Science ®Google Scholar
• Poudyal A, Howden BP, Bell JM, et al. In vitro pharmacodynamics of colistin against multidrug-resistant Klebsiella pneumoniae. J Antimicrob Chemother. 2008;62(6):1311–1318. doi:10.1093/jac/dkn425
   PubMed Web of Science ®Google Scholar
• Kvitko CH, Rigatto MH, Moro AL, et al. Polymyxin B versus other antimicrobials for the treatment of pseudomonas aeruginosa bacteraemia. J Antimicrob Chemother. 2011;66(1):175–179. doi:10.1093/jac/dkq390
   PubMed Web of Science ®Google Scholar
• Medeiros GS, Rigatto MH, Falci DR, et al. Combination therapy with polymyxin B for carbapenemase-producing Klebsiella pneumoniae bloodstream infection. Int J Antimicrob Agents. 2019;53(2):152–157. doi:10.1016/j.ijantimicag.2018.10.010
   PubMed Web of Science ®Google Scholar
• Falcone M, Daikos GL, Tiseo G, et al. Efficacy of Ceftazidime-avibactam plus aztreonam in patients with bloodstream infections caused by Metallo-β-lactamase-producing enterobacterales. Clinl Infect Dis. 2021;72(11):1871–1878. doi:10.1093/cid/ciaa586
   PubMed Web of Science ®Google Scholar
• Yu Z, Liu X, Du X, et al. Pharmacokinetics/pharmacodynamics of polymyxin B in patients with bloodstream infection caused by carbapenem-resistant Klebsiella pneumoniae. Front Pharmacol. 2022;13:975066. doi:10.3389/fphar.2022.975066
   PubMed Web of Science ®Google Scholar
• Liang Q, Huang M, Xu Z. Early use of polymyxin B reduces the mortality of carbapenem-resistant Klebsiella pneumoniae bloodstream infection. Braz J Infect Dis. 2019;23(1):60–65. doi:10.1016/j.bjid.2018.12.004
   PubMed Web of Science ®Google Scholar
• Mattos KPH, Gouvêa IR, Quintanilha JCF, et al. Polymyxin B clinical outcomes: a prospective study of patients undergoing intravenous treatment. J Clin Pharm Therapeutics. 2019;44(3):415–419. doi:10.1111/jcpt.12801
   PubMed Web of Science ®Google Scholar
• Oliveira MS, Prado GV, Costa SF, et al. Polymyxin B and colistimethate are comparable as to efficacy and renal toxicity. Diag Microbiol Infect Dis. 2009;65(4):431–434. doi:10.1016/j.diagmicrobio.2009.07.018
   PubMed Web of Science ®Google Scholar
• Rigatto MH, Oliveira MS, Perdigão-Neto LV, et al. Multicenter prospective cohort study of renal failure in patients treated with colistin versus Polymyxin B. Antimicrob Agents Chemother. 2016;60(4):2443–2449. doi:10.1128/aac.02634-15
   PubMed Web of Science ®Google Scholar
• Sandri AM, Landersdorfer CB, Jacob J, et al. Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens. Clinl Infect Dis. 2013;57(4):524–531. doi:10.1093/cid/cit334
   PubMed Web of Science ®Google Scholar
• Zavascki AP, Nation RL. Nephrotoxicity of polymyxins: is there any difference between colistimethate and Polymyxin B? Antimicrob Agents Chemother. 2017;61(3). doi:10.1128/aac.02319-16
   PubMed Web of Science ®Google Scholar
• Abdelraouf K, Braggs KH, Yin T, et al. Characterization of polymyxin B-induced nephrotoxicity: implications for dosing regimen design. Antimicrob Agents Chemother. 2012;56(9):4625–4629. doi:10.1128/aac.00280-12
   PubMed Web of Science ®Google Scholar
• Sisay M, Hagos B, Edessa D, et al. Polymyxin-induced nephrotoxicity and its predictors: a systematic review and meta-analysis of studies conducted using RIFLE criteria of acute kidney injury. Pharmacol Res. 2021;163:105328. doi:10.1016/j.phrs.2020.105328
   PubMed Web of Science ®Google Scholar
• Xu Y, Liang P, Liu N, et al. Correlation between the drug concentration of polymyxin B and polymyxin B-associated acute kidney injury in critically ill patients: a prospective study. Pharmacol Res Perspect. 2022;10(5):e01010. doi:10.1002/prp2.1010
   PubMed Web of Science ®Google Scholar
• Han L, Xu FM, Zhang XS, et al. Trough polymyxin B plasma concentration is an independent risk factor for its nephrotoxicity. Br. J. Clin. Pharmacol. 2022;88(3):1202–1210. doi:10.1111/bcp.15061
   PubMed Web of Science ®Google Scholar
• Mattos KP, Lloret GR, Cintra ML, et al. Acquired skin hyperpigmentation following intravenous polymyxin B treatment: a cohort study. Pigm Cell Mel Res. 2016;29(3):388–390. doi:10.1111/pcmr.12468
   PubMed Web of Science ®Google Scholar
• Mattos KPH, Cintra ML, Gouvêa IR, et al. Skin hyperpigmentation following intravenous polymyxin B treatment associated with melanocyte activation and inflammatory process. J Clin Pharm Therapeutics. 2017;42(5):573–578. doi:10.1111/jcpt.12543
   PubMed Web of Science ®Google Scholar
• Liu J, Shao M, Xu Q, et al. Low-dose intravenous plus inhaled versus intravenous polymyxin B for the treatment of extensive drug-resistant Gram-negative ventilator-associated pneumonia in the critical illnesses: a multi-center matched case-control study. Ann Intens Care. 2022;12(1):72. doi:10.1186/s13613-022-01033-5
   PubMed Web of Science ®Google Scholar
• Gothwal S, Meena K, Sharma SD. Polymyxin B induced generalized hyperpigmentation in neonates. Indian J Pediatr. 2016;83(2):179–180. doi:10.1007/s12098-015-1798-z
   PubMed Web of Science ®Google Scholar